Updated:
Triathlon Medical Partners
Triathlon Medical Partners launched in 2003 in Cincinnati, Ohio, co-founded by Managing Partners Suzette Dutch and John Rice.
Triathlon Medical Partners
Triathlon Medical Partners launched in 2003 in Cincinnati, Ohio, co-founded by Managing Partners Suzette Dutch and John Rice. The firm grew out of a recognized gap in specialized, early-to-growth stage capital for life sciences companies in the US Midwest and Southeast, regions often overlooked by coastal venture funds. Dutch and Rice built a partnership that combines deep operational experience in biomedical engineering with a venture capital discipline tailored to regulated healthcare markets. Triathlon deploys capital primarily through equity investments in early-stage and expansion-stage biomedical companies. The firm concentrates on three core sectors: medical devices, drug delivery platforms, and diagnostics. Triathlon typically leads or co-leads rounds, seeking board representation and applying an active partnership model to portfolio companies navigating FDA regulatory pathways and commercial adoption curves. Confirmed historical investments include CardioMEMS (acquired by St. Jude Medical) and OrthoHelix Surgical Devices (acquired by Tornier). The firm invests predominantly in North American companies, with a recurring emphasis on portfolio companies headquartered in Ohio, Indiana, and the broader Midwest corridor. Triathlon raised a series of institutionally-structured funds, including Triathlon Medical Ventures III, which closed in 2014 (per SEC filings). The firm operates with a compact team of investment professionals supplemented by an extended network of clinical and regulatory advisors drawn from academic medical centers and health systems. This model allows Triathlon to conduct deep technical diligence without the overhead of a large generalist fund. The firm has maintained a consistent pace of investment across market cycles, reflecting a thesis-driven approach that is agnostic to software hype cycles. The firm's structural differentiator is its tight geographic and sector focus: a Midwest-headquartered firm that does not dilute its thesis chasing coastal IT deals or broad platform creation. Triathlon's sustained commitment to capital-intensive, approval-dependent biomedical companies in secondary US markets creates a sourcing advantage in a venture landscape increasingly dominated by large multi-stage generalist firms. The fund's lifecycle discipline — returning capital to limited partners through trade sales rather than holding for IPO optionality — further distinguishes its investor alignment strategy.
General information
Firm type
Venture Capital
Year founded
2003
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Cincinnati
Corporate office
Cincinnati, OH, United States
Principals
Suzette Dutch
Managing Partner
John Rice
Managing Partner
Sector focus
Frequently asked questions
What types of companies does Triathlon Medical Partners invest in?
Triathlon focuses on biomedical companies across three main sectors: medical devices, drug delivery platforms, and diagnostics. The firm targets companies that have developed a working prototype or have early clinical data and are preparing for regulatory submission or initial commercialization. Triathlon avoids biotech therapeutics and health IT software in favor of engineered products that require FDA clearance.
Does Triathlon lead investment rounds?
Yes, Triathlon typically leads or co-leads financing rounds in its portfolio companies. The firm often secures a board seat as part of its investment terms and works actively with management on regulatory strategy, clinical trial design, and commercial planning. This hands-on approach is a core part of its value proposition to both entrepreneurs and co-investors.
Is Triathlon Medical Partners a single-state investor or does it invest nationally?
While Triathlon is headquartered in Cincinnati and emphasizes sourcing in the Midwest and Southeast, the firm invests nationally within the United States. Its geographic concentration in the Midwest reflects a strategic choice to operate in regions with high biomedical research output but lower venture competition compared to Boston or San Francisco.
How does Triathlon exit its investments?
Triathlon has historically pursued exits through strategic acquisitions by larger medical device or healthcare companies rather than through initial public offerings. Confirmed trade sales of portfolio companies include CardioMEMS to St. Jude Medical and OrthoHelix Surgical Devices to Tornier. The firm structures its fund lifecycle to prioritize these acquisition outcomes.
Who runs investment decisions at Triathlon Medical Partners?
Investment decisions are led by Managing Partners Suzette Dutch and John Rice, who co-founded the firm in 2003. They draw on a network of clinical advisors from academic medical centers to support technical diligence, but the partnership itself maintains a flat decision-making structure without a large hierarchy.
Does Triathlon Medical Partners raise continuously-operating funds or structured vehicles with defined lives?
Triathlon raises traditional closed-end venture capital funds with defined investment periods and fund lives. Its most recent publicly documented vehicle, Triathlon Medical Ventures III, closed in 2014 (per SEC filings). The firm has since continued investing under a subsequent fund series, consistent with standard institutional venture fund structures.
What differentiates Triathlon from generalist healthcare venture funds?
Triathlon does not invest in biotechnology therapeutics, health IT platforms, or general healthcare services. Its exclusive focus on engineered medical products — devices, diagnostics, and drug delivery systems — combined with its operational emphasis on FDA regulatory strategy, sets it apart from broad life sciences funds. The firm's Midwest base further shapes a deal flow network distinct from coastal venture clusters.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: